[1] McNutt M. Cancer immunotherapy[J]. Science, 2013, 342: 1432-1433.
[2] Schreiber R D, Old L J, Smyth M J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
[3] Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy[J]. Oncoimmunology, 2014, 3 (1): e27048-1-20.
[4] Li S, Schmitz K R, Jeffrey P D, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab[J]. Cancer Cell, 2005, 7(4): 301-311.
[5] van Cutsem E, Kohne C H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. The New England Journal of Medicine, 2009, 360(14):1408-1417.
[6] Kuenen B, Witteveen P O, Ruijter R, et al. A phase i pharmacologic study of necitumumab (imc- 11f8), a fully human igg1 monoclonal antibody directed against egfr in patients with advanced solid malignancies[J]. Clinical Cancer Research, 2010, 16(6): 1915-1923.
[7] Ellis L M, Hicklin D J. Vegf-targeted therapy: Mechanisms of antitumour activity[J]. Nature Reviews Cancer, 2008, 8(8): 579-591.
[8] Junttila M R, de Sauvage F J. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467): 346- 354.
[9] Vedi A, Ziegler D S. Antibody therapy for pediatric leukemia[J]. Frontiers in Oncology, 2014, 4: 82.
[10] Sarnaik A A, Weber J S. Recent advances using anti-ctla-4 for the treatment of melanoma[J]. The Cancer Journal, 2009, 15(3): 169-173.
[11] Brahmer J R, Drake C G, Wollner I, et al. Phase i study of singleagent anti-programmed death-1 (mdx-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. Journal of Clinical Oncology, 2010, 28(19): 3167-3175.
[12] Kirkwood J M, Tarhini A A, Panelli M C, et al. Next generation of immunotherapy for melanoma[J]. Journal of Clinical Oncology, 2008, 26(20): 3445-3455.
[13] Weiner L M, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy[J]. Nature Reviews Immunology, 2010, 10(5): 317-327.
[14] Grutter C, Wilkinson T, Turner R, et al. A cytokine- neutralizing antibody as a structural mimetic of 2 receptor interactions[J]. Proceedings of the National Academy of Sciences, 2008, 105(51): 20251-20256.
[15] ArandaF,VacchelliE,EggermontA,etal.Trialwatch: Immunostimulatory monoclonal antibodies in cancer therapy[J]. Oncoimmunology, 2014, 3 (1): e27297-1-11.
[16] Scott A M, Wolchok J D, Old L J. Antibody therapy of cancer[J]. Nature Reviews Cancer, 2012, 12(4): 278-287.
[17] Baldo B A. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses[J]. Oncoimmunology, 2013, 2(10): e26333-1-15.
[18] Palucka K, Banchereau J. Dendritic- cell- based therapeutic cancer vaccines[J]. Immunity, 2013, 39(1): 38-48.
[19] Mocellin S, Mandruzzato S, Bronte V, et al. Part i: Vaccines for solid tumours[J]. The Lancet Oncology, 2004, 5(11): 681-689.
[20] Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: Peptide vaccines in cancer therapy[J]. Oncoimmunology, 2013, 2(12): e26621- 1-11.
[21] Drake C G, Lipson E J, Brahmer J R. Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer[J]. Nature Reviews Clinical Oncology, 2014, 11(1): 24-37.
[22] Cuppens K, Vansteenkiste J. Vaccination therapy for non-small-cell lung cancer[J]. Current Opinion in Oncology, 2014, 26(2): 165-170.
[23] Anguille S, Smits E L, Lion E, et al. Clinical use of dendritic cells for cancer therapy[J]. The Lancet Oncology, 2014, 15(7): e257-e267.
[24] Ruiz R, Hunis B, Raez L E. Immunotherapeutic agents in non-smallcell lung cancer finally coming to the front lines[J]. Current Oncology Reports, 2014, 16(9): 400-1-10.
[25] Herrera Z M, Ramos T C. Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients[J]. Cancer Immunology, Immunotherapy, 2014, 63(7): 737-747.
[26] McCarthy F, Roshani R, Steele J, et al. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (nsclc) [J]. Journal of Leukocyte Biology, 2013, 94(6): 1201-1206.
[27] Karan D, Holzbeierlein J M, Van Veldhuizen P, et al. Cancer immunotherapy: A paradigm shift for prostate cancer treatment[J]. Nature Reviews Urology, 2012, 9(7): 376-385.
[28] Geary S M, Lemke C D, Lubaroff D M, et al. Proposed mechanisms of action for prostate cancer vaccines[J]. Nature Reviews Urology, 2013, 10(3): 149-160.
[29] van den Boorn J G, Hartmann G. Turning tumors into vaccines: Coopting the innate immune system[J]. Immunity, 2013, 39(1): 27-37.
[30] Jacobs J J, Snackey C, Geldof A A, et al. Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer[J]. Anticancer Research, 2014, 34(6): 2689-2700.
[31] Xu L W, Chow K K, Lim M, et al. Current vaccine trials in glioblastoma: A review[J]. Journal of Immunology Research, 2014, 2014: 796856-1-10.
[32] Kalos M, June C H. Adoptive t cell transfer for cancer immunotherapy in the era of synthetic biology[J]. Immunity, 2013, 39(1): 49-60.
[33] Weber J S. At the bedside: Adoptive cell therapy for melanomaclinical development[J]. Journal of Leukocyte Biology, 2014, 95(6): 875-882.
[34] Besser M J, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent- to- treat analysis and efficacy after failure to prior immunotherapies[J]. Clinical Cancer Research, 2013, 19(17): 4792- 4800.
[35] Kirk R. Immunotherapy: Adoptive cell therapy simplified[J]. Nature Reviews Clinical Oncology, 2013, 10(7): 368.
[36] Dudley M E, Gross C A, Somerville R P, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumorinfiltrating lymphocytes for adoptive cell therapy for patients with melanoma[J]. Journal of Clinical Oncology, 2013, 31(17): 2152-2159.
[37] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine- induced killer (cik) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opinion on Biological Therapy, 2012, 12(6): 673-684.
[38] Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J]. Clinical Cancer Research, 2012, 18(6): 1751-1759.
[39] Zhao H, Fan Y, Li H, et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: A retrospective study of 165 patients[J]. Cancer Biotherapy & Radiopharmaceuticals, 2013, 28: 303-309.
[40] Yu X, Zhao H, Liu L, et al. A randomized phase ii study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma[J]. Jornal of Clinical Immunology, 2014, 34(2): 194-203.
[41] Li X D, Xu B, Wu J, et al. Review of Chinese clinical trials on cik cell treatment for malignancies[J]. Clinical & Translational Oncology, 2012, 14(2): 102-108.
[42] Ren J, Di L, Song G, et al. Selections of appropriate regimen of highdose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: Reargument of such contentious therapeutic preferences[J]. Clinical & Translational Oncology, 2013, 15(10): 780-788.
[43] Zhao M, Li H, Li L, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients[J]. Experimental & Therapeutic Medicine, 2014, 7(5): 1403-1407.
[44] Shi S B, Tang X Y, Tian J, et al. Efficacy of erlotinib plus dendritic cells and cytokine- induced killer cells in maintenance therapy of advanced non- small cell lung cancer[J]. Journal of Immunotherapy, 2014, 37(4): 250-255.
[45] Gao D, Li C, Xie X, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients[J]. PLoS One, 2014, 9 (4): e93886-1-9.
[46] Wang Q J, Wang H, Pan K, et al. Comparative study on anti-tumor immune response of autologous cytokine- induced killer (cik) cells, dendritic cells-cik (dc-cik), and semi-allogeneic dc-cik[J]. Chinese Journal of Cancer, 2010, 29(7): 641-648.
[47] Aranda F, Vacchelli E, Obrist F, et al. Trial watch: Adoptive cell transfer for anticancer immunotherapy[J]. Oncoimmunology, 2014, 3: e28344-1-13.
[48] Fisher J P, Heuijerjans J, Yan M, et al. Gammadelta t cells for cancer immunotherapy: A systematic review of clinical trials[J]. Oncoimmunology, 2014, 3(1): e27572-1-10.
[49] Rubnitz J E, Inaba H, Ribeiro R C, et al. Nkaml: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia[J]. Journal of Clinical Oncology, 2010, 28(6): 955-959.
[50] Miller J S, Soignier Y, Panoskaltsis- Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical nk cells in patients with cancer[J]. Blood, 2005, 105(8): 3051-3057.
[51] Davies J O, Stringaris K, Barrett J A, et al. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease[J]. Cytotherapy, 2014, doi: 10.1016/j.jcyt.2014.03.009.
[52] Humphries C. Adoptive cell therapy: Honing that killer instinct[J]. Nature, 2013, 504(7480): 13-15.
[53] Kershaw M H, Westwood J A, Slaney C Y, et al. Clinical application of genetically modified t cells in cancer therapy[J]. Clinical & Translational Immunology, 2014, 3: e16-1-7.
[54] Maus M V, Grupp S A, Porter D L, et al. Antibody-modified t cells: Cars take the front seat for hematologic malignancies[J]. Blood, 2014, 123(17): 2625-2635.
[55] Han E Q, Li X L, Wang C R, et al. Chimeric antigen receptorengineered t cells for cancer immunotherapy: Progress and challenges[J]. Journal of Hematology & Oncology, 2013, 6: 47-1-7.
[56] Raval R R, Sharabi A B, Walker A J, et al. Tumor immunology and cancer immunotherapy: Summary of the 2013 sitc primer[J]. Journal for Immunotherapy of Cancer, 2014, 2: 141-152.
[57] DeFrancesco L. Car-t cell therapy seeks strategies to harness cytokine storm[J]. Nature Biotechnology, 2014, 32(7): 604.
[58] Tey S-K. Adoptive t-cell therapy: Adverse events and safety switches[J]. Clinical & Translational Immunology, 2014, 3: e17-1-7.
[59] You L, He B, Xu Z, et al. Future directions: Oncolytic viruses[J]. Clinical Lung Cancer, 2004, 5(4): 226-230.
[60] Prestwich R J, Errington F, Diaz R M, et al. The case of oncolytic viruses versus the immune system: Waiting on the judgment of solomon[J]. Human Gene Therapy, 2009, 20(10): 1119-1132.
[61] Kaufman H L, Kim D W, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding gm- csf in patients with stage iiic and iv melanoma[J]. Annals of Surgical Oncology, 2010, 17(3): 718-730.
[62] Atherton M J, Lichty B D. Evolution of oncolytic viruses: Novel strategies for cancer treatment[J]. Immunotherapy, 2013, 5(11): 1191- 1206.
[63] Kaufman H L, Bines S D. Optim trial: A phase iii trial of an oncolytic herpes virus encoding gm-csf for unresectable stage iii or iv melanoma[J]. Future Oncol, 2010, 6(6): 941-949.
[64] Thorne S H. Immunotherapeutic potential of oncolytic vaccinia virus[J]. Frontiers in Oncology, 2014, 4: 155.
[65] Moehler M, Goepfert K, Heinrich B, et al. Oncolytic virotherapy as emerging immunotherapeutic modality: Potential of parvovirus h-1[J]. Frontiers in Oncology, 2014, 4: 92.
[66] Finke J H, Rayman P A, Ko J S, et al. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics[J]. The Cancer Journal, 2013, 19(4): 353-364.
[67] Golden E B, Pellicciotta I, Demaria S, et al. The convergence of radiation and immunogenic cell death signaling pathways[J]. Frontiers in Oncology, 2012, 2: 88.
[68] Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: The importance of dose and fractionation[J]. Frontiers in Oncology, 2014, 4: 1.
[69] Sachamitr P, Hackett S, Fairchild P J. Induced pluripotent stem cells: Challenges and opportunities for cancer immunotherapy[J]. Frontiers in Immunology, 2014, 5: 176.
